People On The Move: Appointments At Stada And Angelini Pharma
Executive Summary
A round-up of notable consumer heath appointments: Stada has hired Sanofi's Stéphane Jacqmin as head of emerging markets; and Angelini has appointed Gilead's Jacopo Andreose as CEO of its Pharma business.
Stada Hires Sanofi's Jacqmin
Stada has hired Sanofi Consumer Healthcare’s Stéphane Jacqmin as head of emerging markets with effect from 1 January 2023. He replaces Carsten Cron who is set to leave the German OTC and generics specialist after almost five years with the company.
Appointed for his extensive leadership and management experience in consumer health and fast-moving consumer goods, Jacqmin will deport directly to Stada CEO Peter Goldschmidt and take a seat on the firm’s executive committee.
Jacqmin has spent 10 years with Sanofi Consumer Healthcare, serving for the past 18 months as region head of Latin America. Other roles have included zone head for Turkey, Middle East and Greater China and overseeing the integration of the acquired Boehringer Ingelheim consumer health portfolio across South-East Asia.
Having started his career at Unilever working in Europe and North America, Jacqmin spent around four years in southern Africa with Danone before moving to Reckitt to lead its healthcare and household business as general manager in the Czech Republic and Slovakia.
Commenting on the appointment, Goldschmidt said Jacqmin’s knowledge and expertise would help Stada further accelerate growth in emerging markets. “His extensive experience in regions including South-East Asia, China and the Middle East will be invaluable in capitalizing on the many opportunities open to Stada across Consumer Healthcare, Generics and Specialty Care,” Goldschmidt stated.
Thanking Cron for his efforts, Goldschmidt noted that under his leadership Stada had made “great strides in expanding its presence in emerging markets, not least by introducing Consumer Healthcare brands in key countries, expanding our Generics offering, and in-licensing several Specialty medicines.”
Angelini Appoints Pharma CEO
Angelini Industries has appointed Jacopo Andreose as CEO of Angelini Pharma, effective from 6 February.
Joining the Italy-based firm from Gilead Sciences, Andreose will oversee Angelini Pharma’s activities in the consumer health, brain health and rare diseases sectors, through a business which operates in 20 countries and employs around 3,000 people.
Serving as Gilead’s senior vice president for the intercontinental region and global patient solutions for the past 18 months, Andreose brings to Angellini over 20 years of experience in senior management positions in the pharma industry. Prior to joining Gilead in 2020, he has previously worked for GlaxoSmithKline/ViiV Healthcare, Bristol-Myers Squibb and Abbott, covering strategic and operational roles in Italy, the US, Europe and Asia.
"We are delighted to welcome Jacopo Andreose, who we have chosen for his extensive international experience and in-depth knowledge of the sector,” commented Sergio Marullo di Condojanni and Thea Paola Angelini, respectively CEO and executive vice president of Angelini Industries. “We are confident that Jacopo will make a significant contribution to the development and growth path of Angelini Pharma, which for over a century has prioritized the health and care of people.”
Angelini has expanded its European consumer health footprint over the past few years following its acquisition of the global rights, excluding North America, to the ThermaCare OTC pain-relief line from GSK Consumer Healthcare. (Also see "Angelini Sets Up In Germany As It Unveils ThermaCare Plans" - HBW Insight, 7 Apr, 2020.)